NCT Number: NCT07341048
Polycythemia vera (PV) is a rare haematological disorder characterized by an excessive production of red blood cells, associated with the somatic JAK2 V617F mutation. Clinical manifestations are varied and often include exercise intolerance but the underlying mechanisms remain poorly understood.
Physical activity is recommended in the management of chronic diseases, but it must be tailored to the physiological profile of the patient. A cardiopulmonary exercise test (CPET) is essential to ensure safety, detect possible contraindications, and assess maximal oxygen uptake (VO₂max), a key indicator of aerobic performance.
This prospective, experimental, non-randomized study will include patients with PV followed at Lyon Sud University Hospital and for which a CPET is scheduled in their routine clinical follow-up. The primary objective is to compare VO₂max between two groups of patients: moderate (<10%) versus marked (≥10%) extent of blood viscosity increase after the completion of the CPET. The main hypothesis is that a significant increase in blood viscosity during exercise (≥10%) is a major limiting factor in oxygen transport and leads to a reduced VO₂max, reflecting impaired exercise tolerance.
Secondary analyses will focus on hemorheological parameters, tissue oxygenation, and cardiorespiratory and metabolic responses. The study aims to better understand the biological and physiological determinants of exercise intolerance in this population.
Trial opening soon.
Get Notified18 year–70 year
All sexes
Interventional
Not applicable
Lyon, 69001, France
Emeric Stauffer, Dr
CONTACT
Emeric Stauffer, Dr
PRINCIPAL_INVESTIGATOR
Mael Heiblig, Dr
SUB_INVESTIGATOR
Marie Ducray, Phd
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Research samples: Blood rheology: hematocrit, blood viscosity, deformability and erythrocyte aggregation, viscoelasticity
Other names: the level of tissue oxygenation and hemoglobin oxygenation that will be measured by near-infrared spectroscopy (NIRS).
Time frame: Measurements will be performed at baseline (pre-test), at 3 minutes post-CPET, and at 60 minutes post-CPET
Blood viscosity will be measured using a cone-plate viscometer (Brookfield, model LVDVII+ PRO, cone CPE 40) on native hematocrit blood, at 7 different shear rates: 2.25, 4.5, 11.5, 22.5, 45, 90, and 225 s-¹, using an ascending ramp shear protocol.
Time frame: Measurements will be performed at baseline (pre-test), at 3 minutes post-CPET, and at 60 minutes post-CPET.
Analyses will be performed on EDTA tubes. Erythrocyte deformability will be measured by ektacytometry at 9 shear stresses (0.3-30 Pa) under isotonic conditions. Maximal elongation index (EImax) and shear stress for 50% deformation (SS₁/₂) will be recorded. Aggregation/disaggregation will be assessed by syllectometry at 40% hematocrit. Parameters include aggregation index (AI) and minimal shear rate (γmin) for full disaggregation
Time frame: Measurements will be performed at baseline (pre-test), at 3 minutes post-CPET, and at 60 minutes post-CPET
Viscoelastic properties of blood will be assessed using rotational thromboelastometry (ROTEM delta) on citrated blood tubes. The following tests will be performed: NATEM, TEMACT, FIBTEM, and EXTEM. For each test, the following parameters will be measured: clotting time (CT, in seconds), clot amplitude at 5, 10, 20, and 30 minutes (A5, A10, A20, A30, in mm), alpha angle (indicating clot formation velocity, in degrees), maximum clot firmness (in mm), percentage of clot lysis at 30 minutes (LI30), as well as lysis onset time (LOT) and total lysis time (LT), both expressed in seconds
Time frame: Measurement will be performed during the CPET.
Near-infrared spectroscopy (NIRS) will be performed using the Portamon MKIII system (Artinis) with a sampling rate of 100 Hz. This non-invasive technique involves placing surface electrodes on the skin over the vastus lateralis muscle, halfway between the anterior superior iliac spine and the patella. NIRS enables continuous monitoring of changes in oxyhemoglobin (HbO₂) and deoxyhemoglobin (HHb) concentrations, allowing for the calculation of the tissue oxygenation index (TOI)
Contact information is provided by the study sponsor or research team.
Hospices Civils de Lyon
Other
Characterization of Exercise Intolerance in Patients With Polycythemia Vera: Study of Potential Biological and Physiological Determinants.
Acronym: ACTIVAQ
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06785870
Bone Marrow Diseases, Bone Marrow Neoplasms
London, Ontario, Canada
View Trial DetailsNCT07594535
Hematologic Diseases, Hemic and Lymphatic Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT00722527
Blood Platelet Disorders, Bone Marrow Diseases
Salt Lake City, Utah, United States
View Trial DetailsNCT06038630
Acute Pulmonary Embolism, Anemia
Durham, North Carolina, United States
View Trial Details